Article

Abnormal retinal hemodynamics found in patients with Alzheimer's disease

Author(s):

Fort Lauderdale, FL-Abnormalities in the retinal circulation of patients with Alzheimer's disease have been demonstrated for the first time. It is likely that the mechanisms producing reduced blood flow in the retina are related to those that produce cerebral blood flow abnormalities in Alzheimer's disease, Gilbert T. Feke, PhD, reported at the annual meeting of the Association for Research in Vision and Ophthalmology.

"In many cases, visual symptoms are often the initial complaint reported by patients with Alzheimer's disease, and there is evidence from electrophysiologic tests suggesting that morphologic manifestations of Alzheimer's disease may extend to the retina," said Dr. Feke, senior scientist and director of the Ocular Circulation and Imaging Laboratory at Schepens Retina Associates Foundation/Harvard Medical School, Boston. "Impaired cerebral blood flow has been documented in patients with Alzheimer's disease, and, in a 2005 study, impaired cerebral blood flow was evident even in the pre-clinical stage of the disease.

"Among the various mechanisms responsible for reduced cerebral blood flow are beta-amyloid deposition on the arterial side and collagen deposition leading to increased vessel wall thickness on the venous side of the circulation," Dr. Feke said.

Retinal hemodynamics

The investigators measured the blood column diameter, centerline blood speed, and retinal blood flow rate in the major superior temporal retinal vein in one eye of each subject using the Canon CLBF 100 retinal laser Doppler blood flow instrument. The results in the two groups were compared using unpaired t-tests and Mann-Whitney U tests.

There was no significant difference in IOP between the groups, but Snellen visual acuity was decreased (p = 0.031) in the patients with Alzheimer's disease, according to Dr. Feke.

The investigators reported that mean venous blood column diameter was 133 ± 10 µm in the patients with Alzheimer's disease and 147 ± 9 µm in the control group, a statistically significant (p = 0.006) difference. However, the mean venous centerline blood speed was similar in both groups (26.6 ± 9.7 mm/sec and 30.7 ± 5.4 mm/sec, respectively). The resultant mean blood flow rates were 11.2 ± 4.5 µl/min in the patients and 15.6 ± 2.9 µl/min in the controls. The difference in blood flow rate was also statistically significant (p = 0.026).

"We found a marked narrowing of the retinal venous blood column diameter and a reduction in the retinal blood flow rate in the patients compared with the age-matched control subjects using our Canon retinal laser Doppler instrument," he said. "Our ability to 'lock on' to the target vessels provided reliable measurements.

"To the best of our knowledge, this is the first study to demonstrate abnormalities in the retinal circulation of patients with Alzheimer's disease," Dr. Feke said. "It is likely that the mechanisms producing the reduced blood flow in the retina are related to those that produce the cerebral blood flow abnormalities in patients with Alzheimer's disease."

It is tempting to speculate that the narrowing of the venous blood column diameter is related to an increase in the venous wall thickness resulting from collagen deposition as found in cerebral veins, according to Dr. Feke.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.